Kiniksa Pharmaceuticals (KNSA)

• Market cap: $1.49B
• 1 day: 0.49%
• 5 days: 1.93%
• 1 month: -2.92%
• 3 months: -19.70%
• 6 months: 14.52%
• Year to date: 11.12%
• 1 year: 15.41%
• 5 years: 65.12%
• 10 years: 5.75%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 297

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

281% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 16

42% more capital invested

Capital invested by funds: $696M [Q2] → $991M (+$294M) [Q3]

35% more funds holding

Funds holding: 130 [Q2] → 175 (+45) [Q3]

29% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 42

23% more call options, than puts

Call options by funds: $3.13M | Put options by funds: $2.53M

5.09% more ownership

Funds ownership: 92.52% [Q2] → 97.6% (+5.09%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 70% upside
• Avg. target: $38 82% upside
• High target: $40 94% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Anupam Rama 27% 1-year accuracy 16 / 59 met price target	94% upside $40	Overweight Maintained	5 Nov 2024
Evercore ISI Group Liisa Bayko 55% 1-year accuracy 6 / 11 met price target	70% upside $35	Outperform Maintained	30 Oct 2024